CMPS COMPASS Pathways (CMPS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001816590
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
133
13F, latest reported quarter
What the filings say about CMPS
Planned sales (Form 144), 90 days
$1.5M
2 notices
COMPASS Pathways insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for COMPASS Pathways plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 38.5% of the 6,905,774 shares held after it.
- No other insider sold within 30 days.
- 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ATAI Life Sciences AG sold about $16.1M of CMPS on Sep 26, 2024, the largest insider sale at the company on our record; 133 funds added in the latest 13F quarter.Context
- 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on May 20, 2024.
- The trade is 0.2% of the 3,929,413 shares held after it.
- 1 other insider sold within 30 days.
- 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Malievskaia Ekaterina sold about $70.4K of CMPS on May 21, 2024; 1 other insider sold within 30 days and 133 funds added in the latest 13F quarter.Context
- 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on May 20, 2024.
- The trade is 0.2% of the 3,931,687 shares held after it.
- 1 other insider sold within 30 days.
- 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Goldsmith George Jay sold about $70.4K of CMPS on May 21, 2024; 1 other insider sold within 30 days and 133 funds added in the latest 13F quarter.61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
133 funds bought in last quarter
more than 79% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.9% of the float short (float per yahoo 2026-10-26) · 5.9 days to cover · settled 2026-09-30
more than 78% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CMPS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+77.1%12M
Form 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CMPS: institutional holders (13F)
13F holdings, latest reported quarter
12,161,496 sh
$172.1M
10,700,974 sh
$151.4M
6,348,797 sh
$89.8M
5,000,000 sh
$70.8M
4,470,485 sh
$63.3M
Congress trades in CMPS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CMPS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Jenkins Annalisa
Filed 2026-08-10
$345.8K
Jenkins Annalisa
Filed 2026-08-07
$1.1M
CMPS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$5.1M position · as of 2026-06-30
11.5%
ARK Genomic Revolution ETF
$50.7M position · as of 2026-07-31
3.3%
Simplify Propel Opportunities ETF
$1.6M position · as of 2026-06-30
2.1%
AdvisorShares Dorsey Wright ADR ETF
$873.1K position · as of 2026-06-30
2.1%
Royce Smaller-Companies Growth Fund
$2.5M position · as of 2026-06-30
1.1%
ROBO Global Healthcare Technology and Innovation ETF
$639.7K position · as of 2026-07-31
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 2
1 active
2
Phase 3
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.1M
$4.2M
$964.5K
-14%
n/a
2024
$4.3M
$163.4K
$1.8M
-78%
n/a
2023
$2.8M
$2.4M
$1.3M
-49%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 133 funds added last quarter, $1.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CMPS financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM CMPS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM CMPS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$161.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CMPS
| FY Dec 2025 | -$157.2M |
| FY Dec 2024 | -$119.2M |
| FY Dec 2023 | -$97.4M |
| FY Dec 2022 | -$106.0M |
| FY Dec 2021 | -$68.1M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$41.8M |
| Sep 2024 | -$22.2M |
At each fiscal year end
Single quarter
Debt to equity
0.60x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity CMPS
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.19x |
| FY Dec 2023 | 0.13x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.60x |
| Mar 2026 | 0.15x |
| Dec 2025 | n/a |
| Sep 2025 | 0.83x |
| Jun 2025 | 0.19x |
| Mar 2025 | 0.16x |
| Dec 2024 | 0.19x |
| Sep 2024 | 0.15x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.18x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CMPS
| FY Dec 2025 | -4.97x |
| FY Dec 2024 | -3.95x |
| FY Dec 2023 | -3.39x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -3.18x |
| Mar 2026 | -3.16x |
| Dec 2025 | -4.97x |
| Sep 2025 | -5.16x |
| Jun 2025 | -4.79x |
| Mar 2025 | -4.72x |
| Dec 2024 | -3.95x |
| Sep 2024 | -3.53x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-304.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CMPS
| FY Dec 2025 | -529.7% |
| FY Dec 2024 | -81.5% |
| FY Dec 2023 | -58.2% |
| FY Dec 2022 | -39.3% |
| FY Dec 2021 | -29.8% |
| Jun 2026 | -304.4% |
| Mar 2026 | -61.6% |
| Dec 2025 | -529.7% |
| Sep 2025 | -205.8% |
| Jun 2025 | -71.0% |
| Mar 2025 | -60.6% |
| Dec 2024 | -81.5% |
| Sep 2024 | -64.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-94.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CMPS
| FY Dec 2025 | -127.2% |
| FY Dec 2024 | -63.4% |
| FY Dec 2023 | -50.1% |
| FY Dec 2022 | -36.7% |
| FY Dec 2021 | -28.4% |
| Jun 2026 | -94.2% |
| Mar 2026 | -37.8% |
| Dec 2025 | -127.2% |
| Sep 2025 | -94.4% |
| Jun 2025 | -48.3% |
| Mar 2025 | -43.9% |
| Dec 2024 | -63.4% |
| Sep 2024 | -52.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CMPS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-91.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CMPS
| FY Dec 2025 | -251.8% |
| FY Dec 2024 | -81.7% |
| FY Dec 2023 | -62.5% |
| FY Dec 2022 | -47.2% |
| FY Dec 2021 | -34.5% |
| Jun 2026 | -91.0% |
| Mar 2026 | -51.7% |
| Dec 2025 | -251.8% |
| Sep 2025 | -130.0% |
| Jun 2025 | -72.8% |
| Mar 2025 | -65.4% |
| Dec 2024 | -81.7% |
| Sep 2024 | -66.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CMPS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.1B
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value CMPS
| FY Dec 2025 | $544.5M |
| FY Dec 2024 | $123.7M |
| FY Dec 2023 | $350.2M |
| FY Dec 2022 | $198.7M |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.5B |
| Mar 2026 | $297.4M |
| Dec 2025 | $544.5M |
| Sep 2025 | $395.1M |
| Jun 2025 | $71.0M |
| Mar 2025 | $35.5M |
| Dec 2024 | $123.7M |
| Sep 2024 | $253.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-10.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield CMPS
| FY Dec 2025 | -23.7% |
| FY Dec 2024 | -46.1% |
| FY Dec 2023 | -18.0% |
| FY Dec 2022 | -31.0% |
| FY Dec 2021 | -8.6% |
| Jun 2026 | -8.4% |
| Mar 2026 | -22.4% |
| Dec 2025 | -23.7% |
| Sep 2025 | -29.3% |
| Jun 2025 | -56.6% |
| Mar 2025 | -54.3% |
| Dec 2024 | -46.1% |
| Sep 2024 | -24.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CMPS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$179.0M | -$178.2M | -$136.9M | -$110.4M |
| Net income | -$269.8M | -$155.1M | -$118.5M | -$91.5M |
| EPS (diluted) | -3.08 | -2.30 | -2.32 | -2.16 |
| Operating cash flow | -$157.2M | -$119.2M | -$97.4M | -$105.5M |
| Cash | $149.6M | $165.1M | $220.2M | $143.2M |
| Long-term debt | $14.1M | $24.7M | $28.8M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
CMPS Stock Sonar score 4/7 axes
Find similar shapesCompareCMPS ranks highest on institutional and government (74th percentile) and financial health (32nd), and lowest on profitability (22nd), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CMPS filings, in plain words
Are there planned insider sales of CMPS?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.5M of stock; the latest, by Jenkins Annalisa, was filed 2026-08-10.
Read the full summary
Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
